Dianthus Therapeutics vs Yarrow Bioscience
DNTH and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNTH and YARW compare
Dianthus Therapeutics is the larger company, worth 104 times as much as Yarrow Bioscience ($5.0B against $48.2M).
Yarrow Bioscience pays a dividend yielding 111%; Dianthus Therapeutics does not pay one.
Yarrow Bioscience scores higher on the StockData Score (11 against 7 for Dianthus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNTH | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $48.2M |
| Share price | $89.30 | $18.05 |
| Change, 1 year | 144% | −0.55% |
| Change, 5 years | −16.6% | −98.1% |
| Beta (5Y) | 1.44 | 1.55 |
| Employees | 92 | 10 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | – | 84.5× |
| P/B | 4.0× | 2.2× (better) |
| FCF yield | – | −68.7% |
| Fair value | – | $7.33 |
| Margin of safety | – | −146% |
| Growth | ||
| Revenue growth (TTM) | – | 13.8% |
| Revenue growth, 5Y average | – | −51.4% |
| Profitability | ||
| Operating margin | – | −5219% |
| Net margin | – | −4646% |
| FCF margin | – | −5811% |
| Return on equity | −22.6% (better) | −86.9% |
| Return on invested capital | −22.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 30.02 (better) | 15.26 |
| Altman Z-score | 85.71 (better) | −29.60 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | 111% (better) |
| Years of dividend growth | 0 | – |
| Buyback yield | −0.01% | – |
| Shareholder yield | −0.01% | 111% (better) |
| Ownership | ||
| Held by institutions | 118% | 11.6% |
| Held by insiders | 9.1% | 82.1% |
| Insider net buying, 12 months | −$63.8M | – |
| Short interest, % of float | 18.2% | 29.7% |
Go deeper
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.